COLL — Collegium Pharmaceutical, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

27.18

-2.29-7.77%

Overview Short InterestFilings

COLLQT39Collegium Pharmaceutical, Inc.·NASDAQ

Overview Short InterestFilings

27.18-7.77%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PCRX-2.69%$24.35 AMPH-3.20%$20.11 CRON-3.55%$2.99 ETON-1.44%$43.96 EVO+4.00%$2.08 IRWD-5.72%$4.07 ALVO-0.66%$3.79 PAHC+0.30%$34.39

Snapshot

Index	-	P/E	19.26	EPS (ttm)	1.53	Insider Own	20.89%	Shs Outstand	32.43M	Perf Week	-16.73%

Market Cap	955.82M	Forward P/E	3.93	EPS next Y	7.50	Insider Trans	-1.29%	Shs Float	32.05M	Perf Month	-17.70%

Enterprise Value	1.68B	PEG	0.65	EPS next Q	-	Inst Own	-	Short Float	16.33%	Perf Quarter	-25.07%

Income	47.89M	P/S	1.18	EPS this Y	280.64%	Inst Trans	-	Short Ratio	11.53	Perf Half Y	-37.19%

Sales	808.21M	P/B	3.07	EPS next Y	-3.36%	ROA	2.24%	Short Interest	5.23M	Perf YTD	-36.35%

Book/sh	-	P/C	2.47	EPS next 5Y	6.45%	ROE	15.96%	52W High	46.85 -41.98%	Perf Year	-0.94%

Cash/sh	-	P/FCF	2.48	EPS past 3/5Y	- 17.88%	ROIC	6.10%	52W Low	25.83 5.21%	Perf 3Y	33.95%

Dividend Est.	-	EV/EBITDA	2.87	Sales past 3/5Y	18.95% 20.30%	Gross Margin	60.02%	Volatility	5.67% 4.13%	Perf 5Y	18.40%

Dividend TTM	-	EV/Sales	2.08	EPS Y/Y TTM	9.68%	Oper. Margin	19.61%	ATR (14)	1.73	Perf 10Y	141.76%

Dividend Ex-Date	-	Quick Ratio	0.84	Sales Y/Y TTM	26.15%	Profit Margin	5.93%	RSI (14)	27.01	Recom	2.42

Dividend Gr. 3/5Y	-	Current Ratio	1.03	EPS Q/Q	18.12%	SMA20	-15.86%	Beta	0.72	Target Price	58.00

Payout	0.00%	Debt/Eq	2.75	Sales Q/Q	8.99%	SMA50	-15.09%	Rel Volume	2.19	Prev Close	29.47

Employees	423	LT Debt/Eq	3.01	Earnings	Nov 05	SMA200	-25.05%	Avg Volume	445.99K	Price	27.18

IPO Date	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.49% 4.91%	Net Debt/EBITDA	1.24	Volume	978,489	Change	-7.77%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Feb-10-26	Reiterated	Truist Financial	Buy	$55 → $58
Jan-09-26	Reiterated	HC Wainwright & Co.	Buy	$50 → $60
Jan-09-26	Reiterated	Barclays	Overweight	$58 → $56
Jan-07-26	Reiterated	Truist Financial	Buy	$47 → $55
Dec-08-25	Initiated	Barclays	Overweight	$58
Feb-04-25	Reiterated	Piper Sandler	Neutral	$37 → $36
Jan-10-25	Upgrade	Needham	Hold → Buy
Nov-11-24	Reiterated	Jefferies	Buy	$44 → $40
Aug-09-24	Reiterated	Piper Sandler	Neutral	$39 → $37
Jul-30-24	Upgrade	HC Wainwright & Co.	Neutral → Buy	$47

Latest News

Aug-07-26

Aug-07-2601:00PM

Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43Benzinga

Aug-06-26

Aug-06-2602:54PM

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcriptseekingalpha.com

11:02AM

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com

10:51AM

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimateszacks.com

09:04AM

Collegium Pharmaceutical Q2 Earnings Call Highlightsmarketbeat.com

07:30AM

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progressglobenewswire.com

Aug-01-26

Aug-01-2602:12PM

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Ratingseekingalpha.com

Jul-23-26

Jul-23-2608:00AM

Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com

Jul-22-26

Jul-22-2603:40AM

Bessemer Group Inc. Acquires 31,800 Shares of Collegium Pharmaceutical, Inc. $COLLdefenseworld.net

Jul-20-26

Jul-20-2608:33AM

DivcoWest Welcomes Collegium Pharmaceutical to One Lincolnbusinesswire.com

08:00AM

Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Bostonglobenewswire.com

Jul-09-26

Jul-09-2610:41AM

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?zacks.com

Jul-08-26

Jul-08-2609:26AM

4 Defensive Stocks to Take Refuge in as Tech Sell-off Continueszacks.com

Jul-06-26

Jul-06-2605:36AM

New Strong Buy Stocks for July 6thzacks.com

Jul-01-26

Jul-01-2611:45AM

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Whyzacks.com

Company

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	808	781	631	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	323	317	254	—	—	—	—	—	—
Gross Profit	484	463	377	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	241	276	183	—	—	—	—	—	—
Research and Development	0	0	0	—	—	—	—	—	—
Other Operating Expense	86	0	24	—	—	—	—	—	—
Operating Income	159	187	170	—	—	—	—	—	—
Interest Expense	163	82	74	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	82	-12	3	—	—	—	—	—	—
Net Income Before Taxes	77	93	99	—	—	—	—	—	—
Income Taxes	30	30	29	—	—	—	—	—	—
Consolidated Net Income	48	63	69	—	—	—	—	—	—
Net Income From Continuing Operations	48	63	69	—	—	—	—	—	—
Net Income	48	63	69	—	—	—	—	—	—
EPS (Recurring)	1.53	1.98	2.14	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	1.53	1.98	2.14	—	—	—	—	—	—
EPS (Diluted)	1.24	1.73	1.86	—	—	—	—	—	—
EBITDA	588	401	342	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	21.92	26.76	15.40	—	—	—	—	—	—
Price To Sales Ratio	1.08	1.90	1.45	—	—	—	—	—	—
Gross Margin	59.90	59.28	59.75	—	—	—	—	—	—
Operating Margin	19.68	23.94	26.94	—	—	—	—	—	—
Net Margin	5.94	8.07	10.94	—	—	—	—	—	—
Shares Outstanding	32	32	32	—	—	—	—	—	—
Market Capitalization	870	1,482	917	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SANTINI GINO	Director	Jun 08 '26	Option Exercise	16.49	8,700	143,463	112,483	Jun 10
Freund John Gordon	Director	May 18 '26	Sale	34.05	20	681	83,952	May 20
Freund John Gordon	Director	May 15 '26	Sale	34.54	4,127	142,547	83,972	May 18
Freund John Gordon	Director	May 15 '26	Option Exercise	16.49	8,700	143,463	88,099	May 18
Lurker Nancy	Director	May 13 '26	Sale	35.97	4,500	161,861	18,017	May 15
BOHLIN GAREN G	Director	May 11 '26	Option Exercise	16.49	8,700	143,463	70,959	May 13
BOHLIN GAREN G	Director	May 11 '26	Sale	37.18	8,700	323,491	62,259	May 13
Dieter David	EVP & General Counsel	Mar 18 '26	Sale	34.92	13,976	488,099	77,071	Mar 20
Dieter David	EVP & General Counsel	Mar 09 '26	Sale	36.65	6,224	228,110	91,047	Mar 11
Dreyer Scott	EVP & Chief Commercial Officer	Mar 03 '26	Sale	40.41	49,976	2,019,436	71,770	Mar 05
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,856	103,613	Dec 10
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.